2011
DOI: 10.1097/ogx.0b013e31823e0c44
|View full text |Cite
|
Sign up to set email alerts
|

An Update on the Management of Uterine Carcinosarcoma

Abstract: After completing this CME activity, physicians should be better able to appraise the aggressive nature of uterine carcinosarcoma and factors which would help in delaying or preventing recurrence, assess the importance of lymphadenectomy for uterine carcinosarcoma and its effect on survival, and evaluate various recent trials addressing the chemo-radiotherapeutic combinations as adjuvant therapy.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
13
0
1

Year Published

2012
2012
2022
2022

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 16 publications
(14 citation statements)
references
References 46 publications
0
13
0
1
Order By: Relevance
“…2 The Hordaland cohort collected during our study thus is assumed to be representative of a general Norwegian endometrial cancer population. During later years these tumours have increasingly been treated and classified as endometrial carcinomas 171 , in line with national guidelines. 40 Identification of cases and registration of clinical data was otherwise similar for the Haukeland University Hospital and the Hordaland Cohorts.…”
Section: The Hordaland Cohortmentioning
confidence: 99%
“…2 The Hordaland cohort collected during our study thus is assumed to be representative of a general Norwegian endometrial cancer population. During later years these tumours have increasingly been treated and classified as endometrial carcinomas 171 , in line with national guidelines. 40 Identification of cases and registration of clinical data was otherwise similar for the Haukeland University Hospital and the Hordaland Cohorts.…”
Section: The Hordaland Cohortmentioning
confidence: 99%
“…The sarcomatous component may be homologous (endometrial stromal sarcoma, fibrosarcoma or leiomyosarcoma) or heterologous (rhabdomyosarcoma, chondrosarcoma, osteosarcoma or liposarcoma) [1,2,3]. The patients' overall survival is still unsatisfactory due to the high rate of distant recurrences [2,4,5,6,7,8,9]. In general, the overall 5-year survival for all clinical stages of uterine CSs is nearly 30%, increasing to 50% for tumors confirmed only to the uterus [4,6,10,11].…”
Section: Introductionmentioning
confidence: 99%
“…Histologically, both tumor components - epithelial and mesenchymal - are malignant, and they are characterized by an extremely aggressive course leading to an unfavorable prognosis [1,4,5,6]. Uterine CSs are classified as homologous or heterologous tumors, based on the types of sarcomatous differentiation [1,2,3,7].…”
Section: Introductionmentioning
confidence: 99%
“…Dabei steht aufgrund des üblichen Verlaufs und der schlechten Prognose bei solch fortgeschrittenen Stadien einer Tumorerkrankung der Erhalt der Lebensqualität im Zentrum des therapeutischen Bemühens [9,10,11,12]. Hierfür erscheint das in Südasien tradierte «Whole Medical System» Ayurveda besonders geeignet.…”
Section: Einführungunclassified